Propanc Health Group Corp (OTCMKTS:PPCH) Commences Next Stage Of POP1 Research Program

Propanc Health Group Corp (OTCMKTS:PPCH) a growing healthcare firm focusing on the development of novel and proprietary therapies for cancer patients, said that it commenced the next phase of its POP1 research study with the University of Jaen, Spain. The program is meant to evaluate the anti-cancer effects and cellular mechanisms related with proenzymes as an effective treatment for cancer. The objective is to locate new patentable drug candidates as back up compounds to Propanc’s lead product, PRP.

The research details

James Nathanielsz, the Chief Executive Officer of Propanc said that Jaen, Granada and Bath Universities all significantly contributed to company’s initial research. They contributed at a time when the company undertook laboratory trials to explain how PRP functions and to locate patentable opportunities. Propanc ended up jointly submitting a patent with Bath University across the world. The company owns the commercial rights to it.

The significance

Dr Macarena Peran, the lead experimentalist of Propanc brought all the research institutions together on the same platform. The company published key discoveries in reviewed journal. The objective of the company is to aggressively screen and create new compounds that can act as back up products to PRP. The management expects to report an exciting novel treatment class in oncology which suits with existing treatments. The medications will help to reduce the threat of metastasis and tumor recurrence. It is an integral part of development plan.

The profile

Propanc Health Group Corp (OTCMKTS:PPCH) is a development stage healthcare firm with its prime focus on development of novel cancer treatments for cancer patients. The company, together with its scientific and expert oncology consultants has prepared composite and rational formulation of anti-cancer compounds. These products exert a number of actions to prevent or control cancer tumors from spreading throughout the body. The positive results from initial stage of study have prompted the company to start with the next phase of POP1 research study.

Related News

Leave a Reply

Your email address will not be published. Required fields are marked *

Copyrıght 2015 All RIGHTS RESERVED.